Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to U.S. Patent 7, 132, 570 (the “570 patent”) for Teva’s wakefulness product, narcolepsy, NUVIGIL (armodafinil) tablets.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at email@example.com.
These settlements dismiss a pending appeal with the United States Court of Appeals for the Federal Circuit of a trial court decision that found the ‘570 patent to be valid and infringed.
Teva has reached settlements with each of these companies, granting licenses to allow these parties to market their generic products 180 days after Mylan, the first generic company to file an abbreviated new drug application (ANDA) for the 50 mg, 150 mg, and 250 mg dosages of NUVIGIL.
The settlements allow Actavis to launch generic 100 mg and 200 mg dosages in June 2016, and the others may launch these dosages 180 days after Actavis in the 100 mg and 200 mg dosage forms. Additional terms of the settlements are agreed by the parties to remain undisclosed.
Previously, Teva settled its patent infringement litigation regarding the ‘570 patent against Mylan, which allowed Mylan to begin selling generic versions of 50 mg, 150 mg, and 250 mg NUVIGIL under license beginning in June 2016, or earlier under certain circumstances.